It was noted that IGF-1 LR3 might potentially be 1.5 to 2 times as anabolic as IGF-I in inducing weight gain, increasing visceral organ weights, and possibly enhancing feed use efficiency under continuous delivery conditions
13,14,15 By integrating the latest clinical trial data, we explore the efficacy of GLP-1RAs in treating diseases of the nervous, cardiovascular, endocrine, and digestive systems
1) Core toxicology: a narrow physiologic buffer at the top of the therapeutic range Metabolic pathway: ~9095% is detoxified via glucuronidation and sulfation
Whether comparable propagation dynamics occur in three-dimensional tissues, where extracellular matrix constraints, variable cell density, heterogeneous antioxidant buffering, and local repair mechanisms are likely to shape spread, remains insufficiently resolved and presents a translational gap